Lucile Packard Children's Hospital Stanford
cbtn
Principal Investigators
Scientific Committee
Executive Board
Principal Investigator
Michelle Monje, MD, PhD
Michelle Monje, MD, PhD joined the faculty at Stanford University in 2011 as an Assistant Professor of Neurology & Neurological Sciences. Following her undergraduate degree in biology at Vassar College, Dr. Monje received her MD and PhD in Neuroscience from Stanford University. She then completed ne
Scientific Committee
Executive Board
Principal Investigator
Gerald Grant, MD, FACS
Gerald Grant, MD, FACS directs the Blood-brain Barrier Translational Laboratory, focusing on enhancing drug delivery to brain tumors in children.Dr. Grant received his MD from Stanford University in 1994 and trained as a resident in neurosurgery at the University of Washington Medical Center in Seat
Scientific Committee
Executive Board
Principal Investigator
Sonia Partap, MD
Sonia Partap, MD, is Clinical Associate Professor of Neurology & Neurological Sciences and of Pediatrics at Stanford University, and a neuro-oncologist at Lucile Packard Children’s Hospital Stanford. Dr. Partap received both her B.A. and M.D. at the University of Missouri, Kansas City, before comple
about this
Institution
Lucile Packard Children’s Hospital Stanford opened in 1991 and is the heart and soul of Stanford Children’s Health. Nationally ranked and internationally recognized, the 361-bed hospital located in Palo Alto, Calif. is devoted entirely to pediatrics and obstetrics.
The Pediatric Neuro-Oncology program at Packard Children’s includes world-class pediatric neurosurgeons, neuro-radiologists, radiation oncologists, neuro-oncologists, neuropathologists, social workers, neuropsychologists, rehabilitation experts and nurse practitioners.
Packard Children’s experts specialize in surgical techniques that reduce exposure of the brain or spinal column, lower risk, shorten recovery time, and minimize the disruption of healthy tissue. Packard Children’s was also the first hospital in Northern California to deploy ROSA™, the robotic surgical assistant, for pediatric use. ROSA™ makes neurosurgery safer, faster, and more precise.
Researchers at the Stanford University School of Medicine and Packard Children’s are investigating ways to deliver new chemotherapy drugs directly to brain tumors. One such effort, led by CBTTC investigator Dr. Gerald Grant, examines ways to get different kinds of drugs past the blood-brain barrier, the gate-keeping mechanism that keeps dangerous molecules (and potentially helpful drugs) out of the brain. Dr. Grant’s work may open doors to whole new kinds of chemotherapeutic drugs.
Stanford is currently running more than a dozen brain-tumor-related clinical trials, including studies of new immune therapies and chemotherapy drugs, innovative combinations of chemotherapy and radiation, and new medications that may help address the memory and attention problems that patients sometimes experience after treatment.
Supporters may be familiar with Dr. Michelle Monje, who works at this institution. Her work centers on high grade gliomas; predominantly DIPG. She is also currently running a CAR-T trial.
meet the
Team
Site Coordinator
Anthony Bet
Anthony Bet is a Clinical Research Coordinator at Lucile Packard Children's Hospital Stanford in Palo Alto, California.
Crystal L Mackall, MD
Crystal L Mackall MD is the Ernest and Amelia Gallo Family Professor of Pediatrics and Internal Medicine at Stanford University. She serves as Founding Director of the Stanford Center for Cancer Cell Therapy, Associate Director of Stanford Cancer Institute, Leader of the Cancer Immunology and Immuno
Michael R. Angelo, MD, PhD
Mike's academic background spans across the fields of physics, biochemistry, electrical engineering, and medicine. During his residency he became interested in developing novel methods for immunohistochemical multiplexing using mass spectrometry leading to the development of MIBI during his postdoc